Related Experiment Video
Updated: Jul 26, 2026

28:15
Deficient Pms2, ERCC1, Ku86, CcOI in Field Defects During Progression to Colon Cancer
Published on: July 28, 2010
Enhanced intestinal adenomatous polyp formation in Pms2-/-;Min mice
S M Baker1, A C Harris, J L Tsao
1Department of Molecular and Medical Genetics, Oregon Health Sciences University, Portland 97201, USA.
Cancer Research
|March 27, 1998
Summary
Mice lacking the DNA mismatch repair gene Pms2 and a mutated Apc gene developed significantly more intestinal tumors. Pms2 deficiency accelerates tumor formation in a mouse model of colorectal cancer.
Area of Science:
- Genetics
- Cancer Biology
- Molecular Oncology
Background:
- Mutations in DNA mismatch repair (MMR) genes or the adenomatous polyposis coli (APC) gene are implicated in colorectal cancer.
- Understanding the role of MMR in intestinal tumorigenesis is crucial for developing targeted therapies.
Purpose of the Study:
- To investigate the role of the DNA mismatch repair gene Pms2 in intestinal tumorigenesis.
- To determine if Pms2 deficiency exacerbates tumor development in the presence of an Apc mutation.
Main Methods:
- Generation of mice with combined deficiencies in Pms2 and Apc (Min allele).
- Comparative analysis of intestinal adenoma formation in Pms2-deficient, Apc-mutant, and double-mutant mice.
- Histological examination of tumor progression.
Main Results:
- Pms2-deficient mice did not develop intestinal tumors on their own.
- Mice with combined Pms2 deficiency and Apc heterozygosity (Min) showed a threefold increase in small intestinal adenomas and a fourfold increase in colon adenomas compared to Min mice.
- No clear evidence of carcinoma progression was observed despite increased adenoma formation.
Conclusions:
- Pms2 deficiency significantly enhances adenoma formation in the Apc-mutant (Min) mouse model.
- DNA mismatch repair plays a critical role in suppressing intestinal tumor development.
- Further research is needed to explore the mechanisms underlying Pms2's role in preventing carcinoma progression.

